By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Eisai Inc. 

100 Tice Boulevard

Woodcliff Lake  New Jersey  07677  U.S.A.
Phone: 201-692-1100 Fax: 201-692-1804


SEARCH JOBS
Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com.

For more information about Eisai, please visit www.eisai.com


Key Statistics


Email:
Ownership: Subsidiary

Web Site: Eisai Inc.
Employees: Approximately 2,600
Symbol: ESALF.PK
 



Industry
Pharmaceutical






Company News
Rebecca Jolley Appointed Senior Vice President Americas Commercial, Oncology Business Group At Eisai Inc. (ESALF.PK) 12/1/2016 11:56:21 AM
FDA Grants Fast Track Designation For Development Of E2609, Eisai Inc. (ESALF.PK)'s BACE Inhibitor For Early Alzheimer's Disease 11/17/2016 7:45:53 AM
Eisai Inc. (ESALF.PK) Announces Initiation Of Two Phase 3 Clinical Trials With FYCOMPA (Perampanel) 10/28/2016 7:11:44 AM
Eisai Inc. (ESALF.PK)'s LENVIMA (lenvatinib) Nominated For Galien Foundation's Best Pharmaceutical Product 10/27/2016 9:32:44 AM
Eisai Inc. (ESALF.PK), Oklahoma Medical Research Foundation (OMRF) Enter Autoimmune Disease Research Collaboration 10/26/2016 7:07:23 AM
Eisai Inc. (ESALF.PK) Release: Preliminary Results From Lenvatinib + Pembrolizumab Phase 1b Clinical Study In Select Solid Tumors Presented At ESMO 2016 10/14/2016 9:04:28 AM
Eisai Inc. (ESALF.PK) To Present Updates On Lenvatinib In Two Types Of Thyroid Cancer At 86th Annual Meeting Of The American Thyroid Association 9/21/2016 10:38:50 AM
Eisai Inc. (ESALF.PK) Announces New FYCOMPA (Perampanel) Data Presented At The 12th European Congress On Epileptology (ECE) 9/14/2016 3:18:41 PM
Eisai Inc. (ESALF.PK) And Arena (ARNA) Announce FDA Approval Of BELVIQ XR (Lorcaserin Hcl) Extended-Release Tablets 7/19/2016 6:51:01 AM
Eisai Inc. (ESALF.PK) And Arena (ARNA) Announce Regulatory Approval Of VENESPRI (Lorcaserin Hcl) In Mexico 7/14/2016 6:17:42 AM
12345678910...
//-->